• Successful end-to-end clinical pathway for ColoSTAT colorectal cancer test
• Immediate scale-up through direct physician contact and ColoSTAT Access Program
• Validated commercial and logistical pathway to drive revenue growth

Rhythm Biosciences Ltd (ASX: RHY), an Australian medical diagnostics company, has announced the completion of the first commercial sale of its blood-based ColoSTAT colorectal cancer test. This milestone marks the commencement of the company's commercial clinical diagnostic testing operations. The full end-to-end clinical pathway, from blood draw at a collection site through to result delivery to the ordering clinician, has now been successfully completed in a routine clinical setting. This validates that Rhythm's ColoSTAT testing service can be integrated into existing clinical and pathology workflows and is a scalable revenue-generating testing service. With the logistical pathway now validated, Rhythm will immediately expand test volumes directly through primary care physicians and through the ColoSTAT Access Program, which provides a structured entry point for clinicians to begin ordering ColoSTAT and for the company to collect valuable clinical data. Rhythm's Managing Director and CEO, Dr. David Atkins, stated that the company has the infrastructure, logistics, and partnerships in place to scale from this milestone, and the company looks forward to reporting on test volume growth in the coming months.

Rhythm Biosciences is positioned to immediately scale up the commercial rollout of its ColoSTAT colorectal cancer test, leveraging the validated clinical pathway and partnerships to drive revenue growth.